Literature DB >> 12468427

Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML).

Yinghui Guan1, Brigitte Gerhard, Donna E Hogge.   

Abstract

Although many acute myeloid leukemia (AML) colony-forming cells (CFCs) and long-term culture-initiating cells (LTC-ICs) directly isolated from patients are actively cycling, quiescent progenitors are present in most samples. In the current study, (3)H-thymidine ((3)H-Tdr) suicide assays demonstrated that most NOD/SCID mouse leukemia-initiating cells (NOD/SL-ICs) are quiescent in 6 of 7 AML samples. AML cells in G(0), G(1), and S/G(2)+M were isolated from 4 of these samples using Hoechst 33342/pyroninY staining and cell sorting. The progenitor content of each subpopulation was consistent with the (3)H-Tdr suicide results, with NOD/SL-ICs found almost exclusively among G(0) cells while the cycling status of AML CFCs and LTC-ICs was more heterogeneous. Interestingly, after 72 hours in serum-free culture with or without Steel factor (SF), Flt-3 ligand (FL), and interleukin-3 (IL-3), most G(0) AML cells entered active cell cycle (percentage of AML cells remaining in G(0) at 72 hours, 1.2% to 37%, and 0% to 7.6% in cultures without and with growth factors [GFs], respectively) while G(0) cells from normal lineage-depleted bone marrow remained quiescent in the absence of GF. All 4 AML samples showed evidence of autocrine production of 2 or more of SF, FL, IL-3, and granulocyte-macrophage colony-stimulating factor (GM-CSF). In addition, 3 of 4 samples contained an internal tandem duplication of the FLT3 gene. In summary, quiescent leukemic cells, including NOD/SL-ICs, are present in most AML patients. Their spontaneous entry into active cell cycle in short-term culture might be explained by the deregulated GF signaling present in many AMLs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12468427     DOI: 10.1182/blood-2002-10-3062

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  88 in total

1.  TNF-α induced epithelial mesenchymal transition increases stemness properties in renal cell carcinoma cells.

Authors:  Linlin Zhang; Min Jiao; Kaijie Wu; Lei Li; Guodong Zhu; Xinyang Wang; Dalin He; Dapeng Wu
Journal:  Int J Clin Exp Med       Date:  2014-12-15

2.  Cytoplasmic localization of wild-type survivin is associated with constitutive activation of the PI3K/Akt signaling pathway and represents a favorable prognostic factor in patients with acute myeloid leukemia.

Authors:  Juana Serrano-López; Josefina Serrano; Vianihuini Figueroa; Antonio Torres-Gomez; Salvador Tabares; Javier Casaño; Noemi Fernandez-Escalada; Joaquín Sánchez-Garcia
Journal:  Haematologica       Date:  2013-06-28       Impact factor: 9.941

Review 3.  Biology and relevance of human acute myeloid leukemia stem cells.

Authors:  Daniel Thomas; Ravindra Majeti
Journal:  Blood       Date:  2017-02-03       Impact factor: 22.113

4.  High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study.

Authors:  François Vergez; Alexa S Green; Jerome Tamburini; Jean-Emmanuel Sarry; Baptiste Gaillard; Pascale Cornillet-Lefebvre; Melanie Pannetier; Aymeric Neyret; Nicolas Chapuis; Norbert Ifrah; François Dreyfus; Stéphane Manenti; Cecile Demur; Eric Delabesse; Catherine Lacombe; Patrick Mayeux; Didier Bouscary; Christian Recher; Valerie Bardet
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

5.  Tumor dormancy in bone.

Authors:  Vera Mayhew; Tolu Omokehinde; Rachelle W Johnson
Journal:  Cancer Rep (Hoboken)       Date:  2019-01-29

Review 6.  Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials.

Authors:  Daniel A Pollyea; Jonathan A Gutman; Lia Gore; Clayton A Smith; Craig T Jordan
Journal:  Haematologica       Date:  2014-08       Impact factor: 9.941

7.  Femoral bone marrow aspiration in live mice.

Authors:  Young Rock Chung; Eunhee Kim; Omar Abdel-Wahab
Journal:  J Vis Exp       Date:  2014-07-05       Impact factor: 1.355

Review 8.  Right on target: eradicating leukemic stem cells.

Authors:  Daniela S Krause; Richard A Van Etten
Journal:  Trends Mol Med       Date:  2007-11-05       Impact factor: 11.951

Review 9.  Progress on potential strategies to target brain tumor stem cells.

Authors:  Xing-gang Mao; Xiang Zhang; Hai-ning Zhen
Journal:  Cell Mol Neurobiol       Date:  2008-09-10       Impact factor: 5.046

10.  Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors.

Authors:  Qinghai Liu; David H Nguyen; Qinghua Dong; Peter Shitaku; Kenneth Chung; On Ying Liu; Jonathan L Tso; Jason Y Liu; Veerauo Konkankit; Timothy F Cloughesy; Paul S Mischel; Timothy F Lane; Linda M Liau; Stanley F Nelson; Cho-Lea Tso
Journal:  J Neurooncol       Date:  2009-05-26       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.